At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
In Brief
A Phase 3 clinical trial evaluating Trastuzumab Deruxtecan for Breast Cancer. Active but no longer recruiting, targeting 506 participants across 81 sites in 18 countries.
Detailed Summary
This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).
Study Details
Timeline
Interventions
Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.